Skip to search formSkip to main contentSkip to account menu

dutogliptin

Known as: ((2R)-1-(((3R)-Pyrrolidin-3-Ylamino)Acetyl)Pyrrolidin-2-Yl)Boronic Acid 
A potent, water soluble, selective and orally bioavailable, boronic acid-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Boronic Acids
PHX1149

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with… 
2018
2018
353Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI
2017
2017
Third-quarter biotech job picture
Company Number of employees cut Details Adolor 30 Restructured and reduced head count by 30% to about 80 to save cash. Amylin… 
2016
2016
TCT-180 Impact of the novel DPP-IV-inhibitor Dutogliptin in combination with G-CSF on survival rates and cardiac remodelling after acute myocardial infarction.
2012
2012
Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
Three-dimensional pharmacophore hypothesis was established based on a set of known DPP-IV inhibitor using PharmaGist software… 
Review
2011
Review
2011
Alogliptin for the treatment of type 2 diabetes.
The pharmacologic management of type 2 diabetes has changed dramatically in the past two decades. We have moved from a situation… 
2010
2010
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12‐week, double‐blind, randomized, placebo‐controlled, multicentre trial
Aim: To determine efficacy and tolerability of dutogliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, in patients with type 2… 
2010
2010
Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients
Abstract Objective: Dutogliptin is a novel, orally available, potent, and selective DPP4 inhibitor that improves glycemic control… 
2010
2010
28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen.
The JPMorgan Healthcare conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)